EDIT

Editas Medicine, Inc.

7.82 USD
+0.00 (+0.06%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Editas Medicine, Inc. stock is up 0.45% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 8 February’s closed higher than January. In the last 5 Unusual Options Trades, there were 4 PUTs, 1 CALL.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
27 Dec 20:02 19 Jan, 2024 10.00 PUT 1212 6825
10 Jan 15:15 19 Jan, 2024 10.00 PUT 399 5611
10 Jan 15:15 19 Jan, 2024 10.00 PUT 289 5611
10 Jan 15:30 19 Jan, 2024 10.00 PUT 3795 5611
22 Feb 16:20 17 Jan, 2025 10.00 CALL 198 1194

About Editas Medicine, Inc.

Editas Medicine, Inc. focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness.